Can we predict stroke in atrial fibrillation?

Clinical Cardiology

Volumn 35, Issue SUPPL. 1, 2012, Pages 21-27

  Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ANTICOAGULANT AGENT; WARFARIN;

AGING; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; MORTALITY; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PREDICTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SEX DIFFERENCE; STROKE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DECISION SUPPORT TECHNIQUES; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84855980583     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20969     Document Type: Review

References (45)

1. Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011; 123: 1501-1508.
2. Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'Research Perspectives in Atrial Fibrillation'. Europace. 2009; 11: 860-885.
3. Watson T, Shantsila E, Lip GY., Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet. 2009; 373: 155-166.
4. Hart RG, Pearce LA, Aguilar MI., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857-867. (Pubitemid 351650486)
5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86. [Erratum in: BMJ. 2002;324:141.]
6. Soejima H, Morimoto T, Saito Y, et al. Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials. Thromb Haemost. 2010; 104: 1085-1088.
7. Stroke Prevention in Atrial Fibrillation Investigators. A differential effect of aspirin in prevention of stroke on atrial fibrillation. J Stroke Cerebrovasc Dis. 1993; 3: 181-188.
8. Mant J, Hobbs FDR, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in atrial fibrillation in the elderly community population: the Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA), a randomised controlled trial. Lancet. 2007; 370: 493-503. (Pubitemid 47212371)
9. Rash A, Downes T, Portner R, et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007; 36: 151-156. (Pubitemid 46455393)
10. Connolly S, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364: 806-817.
11. Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006; 37: 447-451. (Pubitemid 43732003)
12. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367: 1903-1912.
13. ACTIVE Investigators, Connolly SJ, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009; 360: 2066-2078.
14. van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the Atrial Fibrillation Investigators. Stroke. 2009; 40: 1410-1416.
15. Potpara TS, Stankovic GR, Beleslin BD, et al. A 12-year follow-up study of patients with newly-diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation Study. Chest. (in press).
16. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007; 69: 546-554.
17. Hughes M, Lip GY., Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008; 99: 295-304. (Pubitemid 351230959)
18. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA. 2001; 285: 2864-2870. (Pubitemid 32537350)
19. Olesen JB, Fauchier L, Lane DA, et al. Risk factors for stroke and thromboembolism in relation to age amongst patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. (in press).
20. Lin LY, Lee CH, Yu CC, et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation-a nationwide database analysis. Atherosclerosis. 2011; 217: 292-295.
21. Olesen J, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: a nationwide cohort study. BMJ. 2011; 342: d124.
22. Rasmussen LH, Larsen TB, Due KM, et al. Impact of vascular disease in predicting stroke, and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health (DCH) cohort study. J Thromb Haemost. 2011; 9: 1301-1307.
23. Depta JP, Bhatt DL., Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes. Thromb Haemost. 2010; 104: 657-663.
24. Karthikeyan G, Eikelboom JW., The CHADS2 score for stroke risk stratification in atrial fibrillation-friend or foe? Thromb Haemost. 2010; 104: 45-48.
25. Keogh C, Wallace E, Dillon C, Dimitrov BD, Fahey T., Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost. 2011 Aug 31; 106 (3): 528-38. Epub 2011 Jul 28. PubMed PMID: 21800003.
26. Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score = 1. Thromb Haemost. 2010; 103: 833-840.
27. Lane DA, Lip GY., Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. Thromb Haemost. 2009; 101: 802-805. [Erratum in: Thromb Haemost. 2010;104:653.]
28. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31: 2369-2429.
29. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010; 137: 263-272.
30. 2-VASc risk scores in paroxysmal atrial fibrillation patients by continuous arrhythmia burden monitoring. Stroke. 2011; 42: 1768-1770.
31. Van Staa TP, Setakis E, Di Tanna GL, et al. A comparison of risk stratification schema for stroke in 79884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011; 9: 39-48.
32. Lip GY, Frison L, Halperin JL, et al. Identifying patients at high risk for stroke despite anticoagulation. A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010; 41: 2731-2738.
33. Poli D, Lip GY, Antonucci E, Grifoni E, Lane D., Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol. 2011; 22: 25-30.
34. Hobbs FD, Roalfe AK, Lip GY, et al.; on behalf of the Birmingham Atrial Fibrillation in the Aged (BAFTA) investigators and Midland Research Practices Consortium (MidReC) network. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ. 2011; 342: d3653.
35. Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011; 13: 723-746.
36. Hughes M, Lip GY,; Guideline Development Group for the NICE National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007; 100: 599-607. (Pubitemid 47543414)
37. Palareti G, Cosmi B., Bleeding with anticoagulation therapy-who is at risk, and how best to identify such patients. Thromb Haemost. 2009; 102: 268-278.
38. Cairns JA, Connolly S, McMurtry S, et al.; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011; 27: 74-90.
39. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093-1100.
40. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011; 57: 173-180.
41. Olesen JB, Lip GY, Hansen PR, et al. Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost. 2011; 9: 1460-1467.
42. Garcia DA, Lopes RD, Hylek EM., New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost. 2010; 104: 1099-1105.
43. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane DA, Levi M, Marin F, Palareti G, Kirchhof P,; Document reviewers:, Collet JP, Rubboli A, Poli D, Camm J., Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011 May; 13 (5): 723-46.
44. Ahrens I, Lip GY, Peter K., New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010; 104: 49-60.
45. Lip GY., Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score = 1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost. 2010; 103: 683-685.